隆尼达胺可缓解炎症和组织重塑,以小鼠模型的eosinophilic慢性鼻炎:一个单细胞转录学研究研究
1Department of Otolaryngology-Head and Neck Surgery, Pulmonology, Traditional Chinese Medicine, and Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052 Hangzhou, China.
International immunopharmacology
|July 23, 2025
概括
用隆尼达胺 (LND) 抑制hexokinase 2 (HK2) 降低了在eosinophilic慢性鼻炎 (ECRS) 中的炎症和组织重塑. 这为耐火性ECRS管理提供了一个有前途的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 乙酸性慢性鼻炎 (ECRS) 是一种具有挑战性的疾病,治疗选择有限,复发率高.
- 基酶2 (HK2) 是一种关键的酶,在葡萄糖分解中参与炎症,在ECRS病原体中的作用仍然在很大程度上未被探索.
研究的目的:
- 为了研究HK2在ECRS小鼠模型中的作用.
- 在ECRS中评估HK2抑制剂隆尼达胺 (LND) 的治疗潜力.
主要方法:
- 建立了一个ECRS小鼠模型,使用鼻内输入帕帕因.
- 使用单细胞RNA测序 (scRNA-seq) 来分析Hk2表达模式.
- 口服LND用于评估ECRS症状,炎症标志物和鼻膜病理,并通过对人类鼻上皮细胞 (HNEpCs) 的体外研究来补充.
主要成果:
- 在ECRS模型的鼻腔粘膜中观察到升高的Hk2表达.
- 治疗LND显著缓解了ECRS症状,减少了炎症细胞透,细胞因子释放和杯状细胞增生.
- 通过向上皮细胞分化,中性粒细胞招募 (Cxcl1-Cxcr2通路) 和上皮细胞-神经元信号 (Ptn-Ncl通路),LND抑制了炎症和鼻膜重塑.
结论:
- 在临床前的ECRS模型中,隆尼达胺有效抑制鼻腔炎症和组织重塑.
- 抑制HK2呈现出一种潜在的安全和有效的治疗途径,用于管理eosinophilic慢性鼻炎.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
483
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
483
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
469
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
469
01:17Drugs Used in Lower Respiratory Disorders: Overview
595
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
595
01:20Asthma: Pathogenesis and Management
599
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
599